Lv21
150 积分 2026-04-22 加入
TCL-955: Frontline Brentuximab Vedotin and CHP in Patients With Peripheral T-Cell Lymphoma With <10% CD30 Expression: Primary Analysis Results From the Phase 2 SGN35-032 Study
13天前
已关闭
A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience
16天前
已完结
Tislelizumab augment the efficacy of CD19/22 dual‐targeted chimeric antigen receptor T cell in advanced stage relapsed or refractory B‐cell non‐Hodgkin lymphoma
18天前
已完结
Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-T alone in relapsed/refractory large B-cell lymphoma
18天前
已完结
Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study
25天前
已完结
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial
26天前
已完结
Abstract CT244: HR001, a novel CD19-targeted CAR-T cell therapy for patients with relapsed/refractory non-Hodgkin's lymphoma: primary results of a phase II study (HRAIN01-NHL01-II)
30天前
已关闭
Lenalidomide efficacy in activated B‐cell‐like subtype diffuse large B‐cell lymphoma is dependent upon IRF4 and cereblon expression
1个月前
已完结
Propensity Score-Matched Analysis Supports the Survival Benefits of Combination Chimeric Antigen Receptor T-Cell Therapy with Autologous Transplantation in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Insights from a Real-World Study in China
1个月前
已完结
Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin’s lymphoma: 2-year results of a phase 1 trial
1个月前
已完结
皖公网安备34019202002308
